Forest Services
Demand for Compulsory Licensing for Rare Diseases: Balancing Public Health and Patent Rights
Conceptual Framework: Public Health Necessities vs Intellectual Property Rights
The growing demand for compulsory licensing (CL) for rare diseases in India highlights a tension between promoting access to lifesaving drugs and protecting intellectual property rights under the WTO’s TRIPS Agreement. Rare diseases, often classified as “orphan diseases,” pose unique challenges due to their low patient base, high R&D costs, and exorbitantly priced drugs, making policy tools such as compulsory licensing critical. The debate also mirrors the larger global discourse on balancing innovation incentives with equitable healthcare access.UPSC Relevance Snapshot
- GS Paper III: Public health, intellectual property rights, pharmaceutical sector reforms
- GS Paper II: Government policies and interventions in health
- Essay: Science, technology, and ethical implications for humanity
- Prelims: TRIPS Agreement, Compulsory Licensing (CL), Section 84 of the Indian Patents Act
Institutional Framework and Key Provisions
The institutional basis for compulsory licensing lies in India's compliance with the TRIPS Agreement, framed within a domestic legislative framework. These measures are geared toward addressing public health emergencies and ensuring access to affordable medicines.Key legal provisions and institutional roles include:
- Indian Patents Act, 1970: Section 84 allows for compulsory licensing on grounds such as non-availability of patented inventions at reasonable prices or when the invention is not “worked” in India.
- TRIPS Agreement: Permits compulsory licensing as a TRIPS flexibility to address public health priorities.
- National Policy for Rare Diseases, 2021: Provides financial assistance and institutional support for patients of rare diseases via Centers of Excellence (CoE).
- Production Linked Incentive (PLI) Scheme for Pharmaceuticals: Incentivizes domestic manufacturing of orphan drugs.
Key Issues and Challenges
Accessibility and Affordability Challenges
- Exorbitant costs impede access: Drugs for rare diseases often cost crores due to limited commercial viability and high R&D investments.
- Limited domestic production: Dependence on imports increases costs. Domestic pharmaceutical firms are often hesitant to invest in orphan drug development due to market risks.
- National Policy for Rare Diseases (NPRD) limited by funding gaps: Financial assistance of Rs. 50 lakh per patient is insufficient given the high costs of some treatments.
Legal and Institutional Barriers
- Ambiguity in "public health rationale": Compulsory licensing is rarely invoked due to lack of clarity on what constitutes "unmet public health needs."
- Patent litigation risks: Fear of investor retaliation or WTO disputes may limit government willingness to issue CLs frequently.
- Inadequate enforcement of Section 3(d): Anti-evergreening provisions to prevent frivolous patents need stricter implementation to uphold affordability.
Global Diplomacy and Trade Pressures
- Pharmaceutical firms and developed nations often exert pressure through trade agreements and sanctions to limit CL use, claiming it harms innovation.
- Investments in domestic R&D risk being deprioritized due to fears of losing patent protections.
Comparative Context: India vs. Other Countries
The global response to public health crises and rare diseases often hinges on the flexibility of compulsory licensing mechanisms. Below is a comparative table:
| Parameter | India | Brazil | Thailand |
|---|---|---|---|
| Grounds for CL | Not affordable or "worked" domestically | Public health emergencies; price disparity | Lack of access to essential medicines |
| Examples of Use | Nexavar for kidney cancer | HIV/AIDS drugs | HIV drugs like Efavirenz |
| Litigation Threats | High; subject to WTO scrutiny | Moderate; often defended under TRIPS flexibilities | Moderate; proactive stance from public sector agencies |
| Pharmaceutical Industry Reaction | Significant pushback, including from MNCs | Moderate | Limited, as market size is small |
Critical Evaluation
The use of compulsory licensing for rare diseases in India represents a crucial interplay of public health urgency and legal safeguards for intellectual property. While Section 84 offers a strong framework, its use has been minimal due to external pressures and inconsistent domestic implementation. WHO and the Doha Declaration reaffirm CL as a legitimate instrument to address global health inequities. However, India’s lack of clarity on CL policy grounds – especially beyond emergencies – restricts its potential. Further, funding gaps under the National Policy for Rare Diseases and logistical bottlenecks hamper its effectiveness.Structured Assessment
- Policy Design Adequacy: The Indian Patents Act and NPRD 2021 provide a legal foundation, but the absence of streamlined operational guidelines limits real-world impact.
- Governance and Institutional Capacity: Enforcement of Section 84 remains weak due to litigation risks and absence of clear implementation metrics.
- Behavioural and Structural Challenges: Low awareness among stakeholders and structural inefficiencies in R&D funding for orphan drugs persist.
Exam Integration
- Which of the following is NOT a ground for invoking compulsory licensing under the Indian Patents Act, 1970?
- Non-affordability of drugs
- Poor availability in the domestic market
- International trade sanction
- Lack of utilization of patented technology in India
- The TRIPS Agreement allows for compulsory licensing:
- Only in declared health emergencies
- For public health priorities as determined by individual nations
- At the sole discretion of the WTO
- Only for generic drugs
Practice Questions for UPSC
Prelims Practice Questions
- Statement 1: Section 84 of the Indian Patents Act allows for compulsory licensing on the grounds of affordability and local working.
- Statement 2: The TRIPS Agreement prohibits compulsory licensing for rare diseases.
- Statement 3: The Indian Patents Act was enacted in 1970.
Which of the above statements is/are correct?
- Statement 1: High costs of developing orphan drugs discourage domestic companies.
- Statement 2: Legal ambiguity concerning what qualifies as public health needs.
- Statement 3: India has fully established mechanisms for enforcing compulsory licensing.
Which of the above statements is/are correct?
Frequently Asked Questions
What is the significance of compulsory licensing in the context of rare diseases?
Compulsory licensing is vital for ensuring access to lifesaving medications for rare diseases, especially where high research and development costs lead to exorbitant drug prices. It seeks to balance public health needs with intellectual property rights, allowing for the production and distribution of affordable alternatives.
How does the TRIPS Agreement relate to compulsory licensing in India?
The TRIPS Agreement provides the legal foundation for compulsory licensing, outlining provisions that allow countries like India to issue licenses for patented drugs to enhance public health access. India's compliance with these provisions is reflected in the Indian Patents Act and its implementation for essential medicines.
What are the major challenges faced by the National Policy for Rare Diseases in India?
The National Policy for Rare Diseases faces significant challenges, especially regarding funding limitations, which inadequately support the high costs of treatments. Additionally, ambiguity surrounding what constitutes 'public health needs' complicates the invocation of compulsory licensing.
What impact does investor retaliation have on the use of compulsory licensing in India?
Investor retaliation can create a chilling effect that discourages the Indian government from frequently issuing compulsory licenses due to fears of litigation and WTO disputes. This leads to a cautious approach in utilizing compulsory licensing as a public health tool.
How does the production-linked incentive scheme aim to support orphan drug development in India?
The Production Linked Incentive (PLI) Scheme for Pharmaceuticals is designed to promote domestic manufacturing of orphan drugs by providing financial incentives. This initiative seeks to alleviate dependency on imports and enhance the availability of affordable treatments for rare diseases.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.